CSE-1034 versus Ceftriaxone: Efficacy and Safety Analysis from a Randomized, Open-labeled Phase III Study in Complicated Urinary Tract Infections

Lignende værker

• Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
  af: Manu Chaudhary, et al.
  Udgivet: (2018-09-01)
• Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
  af: Manu Chaudhary, et al.
  Udgivet: (2017-07-01)
• 1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
  af: Mir, Mohd Amin, et al.
  Udgivet: (2018)
• Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial
  af: Mir, Mohd Amin, et al.
  Udgivet: (2019)
• 1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
  af: Mandale, Pankaj, et al.
  Udgivet: (2018)